PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery

Antonia Carla Testa, Francesca Moro, Tina Pasciuto, M. C. Moruzzi, A. Di Legge, G. Fuoco, R. Autorino, A. Collarino, Benedetta Gui, Gian Franco Zannoni, Maria Antonietta Gambacorta, Maura Micco', Vittoria Rufini, Giovanni Scambia, Maria Gabriella Ferrandina

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)


Objective: To determine the diagnostic performance of two-dimensional (2D) ultrasound parameters, three-dimensional (3D) power Doppler and contrast-enhanced indices in detecting residual disease in locally advanced cervical cancer patients triaged to neoadjuvant treatment followed by radical surgery. Methods: Between October 2010 and June 2014, we screened 108 women with histologically documented locally advanced cervical cancer Stage IB2–IVA, of whom 88 were included in the final analysis. 2D ultrasound parameters, 3D power Doppler and contrast-ultrasound parameters were assessed 5 weeks after the end of neoadjuvant chemoradiation therapy. The pathological response was defined as complete (absence of any residual tumor after treatment) or partial (including microscopic and/or macroscopic residual tumor at pathology examination). The two response groups were compared and receiver–operating characteristics (ROC) curves generated to determine the best cut-off value of sonographic tumor diameter to predict residual disease. Histology was considered as reference. Results: Complete pathological response to chemoradiation was observed in 40 (45.5%) patients and partial response in 48 (54.5%). The presence of residual disease, as confirmed at pathology examination, was detected by 2D grayscale ultrasound with a sensitivity of 64.6% and specificity of 65%. Color Doppler examination in the cases with lesions visualized on grayscale imaging detected the presence of residual disease, confirmed at pathology, with a sensitivity of 87.1% and specificity of 21.4%. The best area under the ROC curve (0.817) was for the detection of pathological residual disease of at least 6 mm in diameter, using a cut-off value of 12 mm for the largest tumor diameter assessed using 2D grayscale ultrasound (sensitivity, 95%; specificity, 70.6%). Neither 3D vascular indices nor contrast-ultrasound parameters obtained for lesions suspected at ultrasound following chemoradiation differed significantly between patients with histological complete and those with partial response. Conclusions: Our results show that grayscale and color Doppler ultrasound have a low level of diagnostic performance in detecting residual disease after neoadjuvant chemoradiation in patients with locally advanced cervical cancer. The best performance was achieved in detection of macroscopic (≥ 6 mm) residual disease. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Lingua originaleEnglish
pagine (da-a)110-118
Numero di pagine9
Stato di pubblicazionePubblicato - 2018


  • Adult
  • Aged
  • Carcinoma, Squamous Cell
  • Chemoradiotherapy
  • Female
  • Humans
  • Hysterectomy
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm, Residual
  • Obstetrics and Gynecology
  • Prospective Studies
  • Radiological and Ultrasound Technology
  • Radiology, Nuclear Medicine and Imaging
  • Reproducibility of Results
  • Reproductive Medicine
  • Sensitivity and Specificity
  • Ultrasonography, Doppler, Color
  • Uterine Cervical Neoplasms
  • Young Adult
  • cervical cancer
  • chemoradiation
  • ultrasound


Entra nei temi di ricerca di 'PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery'. Insieme formano una fingerprint unica.

Cita questo